Form 8-K April 11, 2017			
UNITED STATES			
SECURITIES AND EXCHANGE COMMISSION			
Washington, D.C. 20549			
Form 8-K			
CURRENT REPORT			
PURSUANT TO SECTION 13 OR 15(d)			
OF THE SECURITIES EXCHANGE ACT OF 1934			
Date of Report (Date of earliest event reported): April 10, 2017			
Intermolecular, Inc.			
(Exact Name of Registrant as Specified in Charter)			


INTERMOLECULAR INC

Delaware 001-35348 20-1616267 (State or Other Jurisdiction (Commission (IRS Employer Identification No.)

of Incorporation) File Number)

3011 N. First Street

	San Jose, California (Address of Principal Executive Offices)	95134 (Zip Code)	
	mber, Including Area Code)		
N/A			
(Former Name or Former A	ddress, if Changed Since Last Report)		
	below if the Form 8-K filing is intended to the following provisions (see General Instru	simultaneously satisfy the filing obligation of action A.2. below):	
Written communications pu	ursuant to Rule 425 under the Securities Ac	et (17 CFR 230.425)	
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)			
US-DOCS\85467595.2			



SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INTERMOLECULAR, INC.

Date: April 11, 2017 By: /s/ Christian F. Kramer Christian F. Kramer

President and Chief Executive Officer

US-DOCS\85467595.2